- Home
- PLUR vs APLT Comparison
PLUR vs APLT Comparison
Compare PLUR & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLUR | APLT |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 38.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PLUR | APLT |
|---|---|---|
| Price | $3.04 | $0.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $12.00 | $1.25 |
| AVG Volume (30 Days) | 47.8K | ★ 27.2M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,326,000.00 | $1,000,000.00 |
| Revenue This Year | $97.38 | $124.18 |
| Revenue Next Year | $293.97 | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 121.74 | N/A |
| 52 Week Low | $3.02 | $0.11 |
| 52 Week High | $7.13 | $1.50 |
Technical Indicators
Market Signals| Indicator | PLUR | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 38.75 | 25.40 |
| Support Level | $3.10 | $0.21 |
| Resistance Level | $3.92 | $0.26 |
| Average True Range (ATR) | 0.31 | 0.02 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 7.03 | 5.13 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.